REMICADE
Biological
Janssen Research & Development, LLC
Total Payments
$21.7M
Transactions
165,256
Doctors
25,414
Companies
5
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.1M | 327 | 40 |
| 2023 | $1.7M | 34,086 | 11,747 |
| 2022 | $2.2M | 55,543 | 13,733 |
| 2021 | $617,138 | 40,160 | 10,726 |
| 2020 | $161,405 | 7,318 | 3,109 |
| 2019 | $3.8M | 7,429 | 2,439 |
| 2018 | $5.4M | 9,663 | 3,567 |
| 2017 | $6.7M | 10,730 | 4,622 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $18.4M | 2,928 | 84.9% |
| Food and Beverage | $2.5M | 160,674 | 11.7% |
| Consulting Fee | $483,226 | 255 | 2.2% |
| Education | $111,929 | 1,248 | 0.5% |
| Travel and Lodging | $63,562 | 111 | 0.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $59,750 | 23 | 0.3% |
| Space rental or facility fees (teaching hospital only) | $23,350 | 17 | 0.1% |
Payments by Type
Research
$18.4M
2,928 transactions
General
$3.3M
162,328 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A multi center prospective long term observational registry of pediatric patients with IBS | Janssen Research & Development, LLC | $7.4M | 0 |
| A multicenter open registry of patients with psoriasis who are candidates for systematic therapy including biologics | Janssen Research & Development, LLC | $6.4M | 2 |
| DEVELOP | Janssen Research & Development, LLC | $2.2M | 0 |
| A Multi Center prospective long term observational registry of pediatric patients with inflammatory bowel disease | Janssen Research & Development, LLC | $1.2M | 0 |
| A Phase 4, Multicenter, Open-label Study of Serum Infliximab Concentrations and Efficacy and Safety of Dose Escalation in Pediatric Patients With Inflammatory Bowel Disease | Janssen Research & Development, LLC | $993,204 | 0 |
| Janssen Diagnostics' Leading Edge Initiative Program | Janssen Scientific Affairs, LLC | $96,460 | 0 |
| The Use of Small bowel Ultrasound to Predict Response to Remicade Induction | Janssen Research & Development, LLC | $43,306 | 0 |
| Individualized IFX dosing; Proof of Concept Study | Janssen Research & Development, LLC | $17,046 | 0 |
| Correlation of Day 4 Infliximab Levels with Outcomes in Ulcerative Colitis | Janssen Research & Development, LLC | $16,774 | 0 |
| Mean SIBDQ to stratify Crohns disease patients: Impact of neuropsychiatric illness, chronic pain and refractory inflammation | Janssen Research & Development, LLC | $9,598 | 0 |
| 12345 | Janssen Pharmaceuticals, Inc | $1.00 | 1 |
Top Doctors Receiving Payments for REMICADE — Page 1017
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Clinical & Laboratory Dermatological Immunology | Ann Arbor, MI | $2.57 | 1 |
| , MD | Rheumatology | Miami, FL | $2.47 | 1 |
| , M.D | Rheumatology | Miami, FL | $2.46 | 1 |
| , MD | Rheumatology | Miami, FL | $2.46 | 1 |
| , PA | Physician Assistant | Wexford, PA | $2.44 | 1 |
| , MD | Rheumatology | Springfield, IL | $2.42 | 1 |
| , MD | Gastroenterology | Santa Maria, CA | $2.40 | 1 |
| , D.O | Family Medicine | Perrysburg, OH | $2.16 | 1 |
| , M.D | Gastroenterology | Annapolis, MD | $2.11 | 1 |
| , PAC | Physician Assistant | Orlando, FL | $2.06 | 1 |
| , M.D | Specialist | Saint Louis, MO | $2.04 | 1 |
| , M.D., F.A.C.G | Gastroenterology | Boulder, CO | $1.98 | 1 |
| , M.D | Rheumatology | Bryn Mawr, PA | $1.63 | 1 |
| , MD | Orthopaedic Surgery | Fort Wayne, IN | $1.00 | 1 |
| , M.D | MOHS-Micrographic Surgery | Beaumont, TX | $0.69 | 1 |
Ad
Manufacturing Companies
- Janssen Research & Development, LLC $18.4M
- Janssen Biotech, Inc. $2.9M
- Janssen Scientific Affairs, LLC $473,322
- Johnson & Johnson Health Care Systems Inc. $21,003
- Janssen Pharmaceuticals, Inc $3,118
Product Information
- Type Biological
- Total Payments $21.7M
- Total Doctors 25,414
- Transactions 165,256
About REMICADE
REMICADE is a biological associated with $21.7M in payments to 25,414 healthcare providers, recorded across 165,256 transactions in the CMS Open Payments database. The primary manufacturer is Janssen Research & Development, LLC.
Payment data is available from 2017 to 2024. In 2024, $1.1M was paid across 327 transactions to 40 doctors.
The most common payment nature for REMICADE is "Unspecified" ($18.4M, 84.9% of total).
REMICADE is associated with 11 research studies, including "A multi center prospective long term observational registry of pediatric patients with IBS" ($7.4M).